Stable docetaxel albumin nanoparticle composition
The allergies of existing docetaxel preparations are solved by combining acid degenerative human albumin with docetaxel and adding osmotic pressure regulators and pH regulators to form a stable docetaxel albumin nanoparticle composition. Response, fluid retention and stability issues improve product safety and stability.
Patent Information
- Application Number
- CN202411190152.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-03-05
- Filing Date
- 2022-03-04
- Publication Date
- 2024-11-08
AI Technical Summary
The existing docetaxel preparations contain ethanol and Tween-80, which lead to severe allergic reactions, fluid retention, affecting the central nervous system and hemolytic reactions. The product compatibility is poor, which limits the convenience of clinical use.
Acid-degenerative human albumin combined with docetaxel, and osmotic pressure regulator and pH regulator are added to form a stable docetaxel albumin nanoparticle composition, optimize particle size and stability, reduce allergic reactions and hemolysis Risk, improve the physical and chemical stability of the product.
It significantly improves the safety and compliance of docetaxel's clinical use, extends the stability of the product, reduces the risk of allergic reactions, enhances the physical and chemical stability of the product, and is suitable for long-term storage and use.
Smart Images

Figure BDA0005014879740000131 
Figure BDA0005014879740000151 
Figure BDA0005014879740000152
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and particularly relates to a composition containing docetaxel albumin nanoparticles. Background Art
[0002] Docetaxel is a semi-synthesized product of a non-cytotoxic precursor (10-deacetylbaccatin III) extracted from the needles of Taxus chinensis. It is a paclitaxel analog that acts on cell microtubules, promoting tubulin polymerization while inhibiting microtubule depolymerization, causing cells to arrest in the G2 / M phase and inhibiting mitosis, thereby killing tumor cells. It has stronger anti-tumor activity than paclitaxel.
[0003] Docetaxel is poorly water-soluble and the currently commercially available preparation is a common injection solution, which was first developed by Sanofi and is marketed under the trade name The usual dosage is once every 3 weeks, intravenous infusion for 1 hour, with a dose of 75 mg / m 2 However, Docetaxel injection, represented by , has the following disadvantages due to the use of ethanol and Tween 80 in the prescription:
[0004] ① Severe allergic reactions require dexamethasone pretreatment, and patient compliance is poor. Tween-80 can cause severe allergic reactions and fluid retention, and anti-allergic drugs need to be taken in advance. For example, starting from the day before the infusion, 16 mg of dexamethasone is taken daily for at least 3 days to prevent allergic reactions and fluid retention; even if dexamethasone is taken in advance, severe allergic reactions have been reported. The instructions clearly state that "6.5% (6 / 92) of patients who received 3 days of dexamethasone preventive treatment reported severe fluid retention."
[0005] ② Ethanol can affect the central nervous system, and the infusion rate needs to be reduced to slow down the symptoms of poisoning. In 2014, the FDA published a "Drug Safety Communication on the Risk of Poisoning with Intravenous Ethanol-Containing Chemotherapy Docetaxel", which stated that the ethanol in docetaxel injection may affect the central nervous system, and reducing the infusion rate may slow down the symptoms of ethanol poisoning, and called for the development of docetaxel preparations that do not contain ethanol.
[0006] ③Tween-80 causes allergic reactions and can only be administered at low concentrations, resulting in poor patient compliance. Tween-80 can cause allergic reactions and can cause hemolysis when the concentration is too high. Therefore, it can only be diluted to a lower concentration for administration, which prolongs the infusion time and results in poor patient compliance.
[0007] ④ The product has poor compatibility and stability, and requires the use of an infusion device that does not contain PVC material, which is inconvenient for clinical use. The instructions mention that "docetaxel pre-injection (10 mg / ml) should be used immediately after preparation. However, its physical and chemical properties show that the stability of the pre-injection is 8 hours regardless of whether it is stored at 2-8°C or at room temperature. The injection (not exceeding 0.74 mg / ml) should be used within 4 hours at room temperature and intravenously dripped for 1 hour", which is inconvenient for clinical use; the instructions clearly mention that the use of PVC infusion devices is not recommended, and contact with PVC infusion devices will cause the di-(2-ethylhexyl) phthalate in the PVC infusion device to leach out, posing a safety hazard.
[0008] To improve the many shortcomings of conventional preparations, Development of docetaxel-loaded intravenous formulation, Nanoxel-PM TM Using polymer-based delivery system (Sa-Won Lee, Min-Hyuk Yun, Seung Wei Jeong, Journal of Controlled Release, 155 (2011) 262–271) discloses the Nanoxel-PM developed by South Korea’s Sanyo Company. TM (Already on the market in Korea, trade name: M), the product uses polyethylene glycol-polylactide (mPEG-PDLLA) polymer as a carrier to prepare docetaxel micelles with an average particle size of 10-50nm and a uniform particle size distribution. Its official website discloses the clinical use method. In order to minimize allergic reactions, pretreatment is necessary. For example, 16 mg of dexamethasone is taken orally every day from the day before administration for 3 consecutive days (https: / / www.samyangbiopharm.com / eng / ProductIntroduce / injection03). Although ethanol and Tween 80 are not used in the prescription of this product, pretreatment is still required clinically.
[0009] Human serum albumin (HSA) is a protein in human plasma, which contains 585 amino acids and has a molecular weight of 66kD. Its concentration in plasma is 42g / L, accounting for about 60% of total plasma protein. In body fluids, human serum albumin can transport fatty acids, bile pigments, amino acids, steroid hormones, metal ions and many therapeutic molecules; at the same time, it can maintain normal osmotic pressure and physiological pH value of blood.
[0010] Protein is a high-molecular compound composed of various amino acids, in which the amino acids are combined through peptide bonds and disulfide bonds to form a peptide chain with a certain order, which is called the primary structure; hydrogen bonds can be formed between the amino groups and the acyl groups in the same polypeptide chain or different polypeptide chains, so that the main chain of the polypeptide chain has a certain regular conformation, including α-helix, β-fold, β-turn and Ω-loop, which are called the secondary structure of the protein; the peptide chain further coils and folds on the basis of the secondary structure to form a complete spatial conformation, which is called the tertiary structure; the spatial structure formed by the aggregation of multiple peptide chains through non-covalent bonds is called the quaternary structure, in which one peptide chain is called a subunit.
[0011] Denaturation of protein refers to the process by which physical or chemical factors affect the internal structure and properties of proteins. It is generally believed that changes or destruction of the secondary and tertiary structures of proteins are the result of denaturation. The methods of protein denaturation are mainly divided into chemical methods and physical methods. Chemical methods include strong acids, strong bases, heavy metal salts, urea, acetone, etc.; physical methods include heating, ultraviolet and X-ray irradiation, ultrasound, violent shaking or stirring, etc.
[0012] Michael Dockal, Daniel C. Carter, Florian Rüker. Conformational Transitions of the Three Recombinant Domains of Human Serum Albumin Depending on pH. (J Biol Chem, 2000, 275 (5): 3042-3050) reported that human serum albumin undergoes conformational transitions under different pH conditions (e.g., NF and FE transformations under acidic conditions, NB transformations under alkaline conditions), which leads to protein denaturation. In the present invention, we define albumin denatured by acid addition as "acid denatured albumin", where the pH of the albumin solution is less than 5.5.
[0013] The production process of human albumin, whether imported or domestic, is basically the same. It is made by purifying healthy human plasma through low-temperature ethanol protein separation and inactivating viruses by heating at 60°C for 10 hours. Commercially available albumin usually adds sodium octanoate as a heat protectant, for example, 0.16 mmol of sodium octanoate is added to every 1g of albumin.
[0014] Since human albumin is an endogenous substance in the human body, it has good biocompatibility and can be used as a natural carrier for hydrophobic drugs to increase the solubility of poorly soluble drugs. Abraxis, a US company, developed paclitaxel (albumin-bound) for injection (trade name: ) was approved by the FDA in 2005 for the treatment of metastatic breast cancer that has failed combination chemotherapy or breast cancer that has recurred within 6 months of adjuvant chemotherapy. It was subsequently approved for the treatment of non-small cell lung cancer, pancreatic cancer, and gastric cancer (Japan).
[0015] Paclitaxel injection Compared with the conventional paclitaxel, the prescription does not contain the solvent polyoxyethylene castor oil that can cause severe allergic reactions, so there is no need to pre-administer anti-allergic drugs, and the drug can be quickly administered at high concentrations, shortening the infusion time to less than 30 minutes, significantly improving patient compliance. Due to the improved safety, the dosage of paclitaxel has been increased from 175 mg / m 2 Can be increased to 260-300 mg / m 2 ; The polyoxyethylene castor oil in the formula will inhibit the binding of paclitaxel to albumin. If the formula does not contain polyoxyethylene castor oil, the unique "gp60-caveolin-SPARC" channel of albumin can be fully utilized to enrich the drug in the tumor area, thereby increasing the efficacy. Currently, researchers from various countries are trying to use human albumin to develop albumin nanoparticles for other drugs, such as docetaxel.
[0016] Among them, patent US2005 / 0004002A1 of Neil P. Desai et al. discloses an emulsification method for preparing docetaxel albumin nanoparticles, wherein the formulation only includes docetaxel and human albumin, the particle size is 50-220 nm, and the particle size does not change substantially before and after lyophilization. However, the stability time of the suspension is relatively short, whether before or after lyophilization, and cannot meet clinical needs.
[0017] Chinese patent CN103054798A first tried to add soybean oil, phospholipids, cholesterol, benzoic acid, etc. as stabilizers in the prescription to improve the stability of the suspension, but all failed. After a lot of experiments and explorations, it was finally determined that adding sodium citrate or a combination of sodium citrate and sodium chloride can significantly improve the stability of the suspension. However, the use of a large amount of salt leads to a high osmotic pressure of the reconstructed suspension, which is highly irritating, causing obvious pain during injection, and even causing local tissue cell permeability damage during injection, which is inconvenient for clinical use.
[0018] The invention also points out that the nanoparticle suspension prepared by the anhydrous form of docetaxel is more stable than the bound water form (such as docetaxel trihydrate or hemihydrate). Example 28 records that in the absence of a stabilizer, when the active ingredient is anhydrous docetaxel (i.e., docetaxel), the nanoparticle filtrate settles on the first day of storage at 4°C, and the sedimentation of hemihydrate and trihydrate occurs in a shorter time; in the presence of a stabilizer, when the active ingredient is anhydrous docetaxel (i.e., docetaxel), at 4°C, the nanoparticle filtrate does not settle for 2 days, and the sedimentation of hemihydrate and trihydrate occurs in a shorter time. Therefore, the patent is limited to the preparation of albumin nanoparticles with anhydrous docetaxel, which greatly limits the range of raw material selection for docetaxel.
[0019] The patent also investigated the pH of the formulation and found that "the increase in pH above 6 increases the physical stability measured in terms of nanoparticle size and formulation sedimentation, and at the same time, increases the amount of docetaxel degradation to 7-epi-docetaxel at room temperature. Therefore, the acceptable pH range for both physical stability and chemical stability is between 6-8.5, the more preferred pH range is 6.5-8, and the optimal range is found to be pH 7.25 to 7.75."
[0020] Although CN103054798A believes that the addition of sodium citrate or a sodium citrate and sodium chloride composition is beneficial to improve the physical stability of docetaxel albumin nanoparticle preparations, Chinese patent CN106137969A points out that the addition of tartaric acid, citric acid, ascorbic acid and other organic acids with a pKa of 2.5-4.5 to the docetaxel albumin composition cannot effectively inhibit the growth of 7-epidocetaxel, and even an increase in 7-epidocetaxel occurs, resulting in poor chemical stability of the composition and affecting the safety of the preparation. However, the selective addition of amino acid substances can make docetaxel albumin stable for a long time, significantly inhibiting the generation of 7-epidocetaxel. In particular, when the amino acid is arginine, after 30 months, the content of 7-epidocetaxel is only 0.72%. The prepared product is re-dissolved and the suspension can be stable at room temperature for more than 8 hours. The patent stipulates that in the docetaxel albumin nanoparticle pharmaceutical composition, the mass ratio of amino acids to docetaxel is not less than 0.5, preferably not less than 1.
[0021] WO2018 / 059304A1 also discloses a method for improving the product quality of an albumin pharmaceutical composition, wherein the pharmaceutical composition comprises albumin and at least one amino acid or its salt having a relative molecular weight of 145-175, wherein the amino acid can be selected from one or more of arginine, histidine and lysine, preferably arginine and / or histidine, and more preferably arginine; the weight ratio of the amino acid or its salt to albumin is 0.1:1 to 10:1, and the amino acid or its salt inhibits the formation or increase in the content of albumin dimers during the preparation, storage and use of the pharmaceutical composition. The albumin pharmaceutical composition can effectively reduce the undesirable responses in the human body caused by albumin polymers and dimers in clinical use, such as rashes, urticaria, allergic reactions and possible immune responses, and further ensure the safety of clinical medication.
[0022] In summary, to improve the quality of docetaxel albumin products, it is necessary to consider both its physical stability (suspension stability) and chemical stability (docetaxel degradation and albumin polymer increase). The docetaxel albumin compositions disclosed in the prior art are, in one way, to add a large amount of chelating agents as stabilizers to improve the physical stability of the product, but the effect on its chemical stability is not investigated; in addition, a large amount of chelating agents improves stability while forming a hypertonic solution, which is inconvenient for clinical use. Another way is to add a large amount of amino acids to the product, which can inhibit the degradation of docetaxel and the increase of albumin polymers, but the effect on physical stability has not been studied in depth, and it is only mentioned that the suspension can be stable at room temperature for more than 8 hours after reconstitution.
[0023] Therefore, finding a method that can simultaneously ensure the physical stability and chemical stability of docetaxel albumin compositions is an urgent problem to be solved in the art. Summary of the invention
[0024] The present invention provides a composition containing docetaxel albumin nanoparticles, wherein the composition comprises docetaxel and acid-denatured albumin.
[0025] Alternatively, the present invention provides a composition containing docetaxel albumin nanoparticles, wherein the composition is prepared from docetaxel and acid-denatured albumin.
[0026] Alternatively, the present invention provides a composition containing docetaxel albumin nanoparticles, wherein the composition is made of docetaxel and acid-denatured albumin, and optionally comprises an osmotic pressure regulator or a pH regulator.
[0027] Wherein, the docetaxel is preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate.
[0028] The acid-denatured albumin is obtained by adding acid to human albumin and adjusting it to an appropriate pH value before denaturing it. Preferably:
[0029] (1) The acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine hydrochloride; and / or
[0030] (2) The appropriate pH value is preferably 3.5 to 5.5, preferably 3.5 to 5.0, more preferably 3.8 to 4.7, more preferably 4.0 to 4.5; and / or
[0031] (3) based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), more preferably 1:(4.0-6.0); and / or
[0032] (4) The content of sodium octanoate in the human serum albumin is not higher than 0.08 mmol / g protein, preferably 0.03-0.08 mmol / g protein, further preferably 0.04-0.08 mmol / g protein, and more preferably 0.04-0.07 mmol / g protein.
[0033] In some embodiments, the particle size of the docetaxel albumin nanoparticles is about 60-200 nm, preferably 90-150 nm, and more preferably 90-135 nm.
[0034] The composition containing docetaxel albumin nanoparticles of the present invention optionally contains an osmotic pressure regulator to adjust the osmotic pressure within an appropriate range. The type of the osmotic pressure regulator is not particularly limited, for example, it can be selected from sodium chloride, glucose, phosphate or citrate, etc., preferably sodium chloride. Its type and dosage can be determined by those skilled in the art according to the specific circumstances such as the type and dosage of the diluent or reconstitution medium used clinically. In some embodiments, the osmotic pressure regulator is sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9): 1, preferably (1-7): 1, preferably (1.5-4.5): 1, and most preferably 2.25: 1.
[0035] Optionally, the composition of the present invention comprises a pH regulator to adjust the pH value within an appropriate range so that the suspension prepared from the composition of the present invention and / or the reconstituted suspension of the composition of the present invention is stable at 25°C for at least 24 hours, preferably at least 30 hours; and / or stable at 2-8°C for at least 7 days, preferably at least 10 days. The "stable" mentioned here means that there is no precipitation of nanoparticles or turbidity of the suspension. The type of the pH regulator is not particularly limited. Preferably, the pH value range is 3.4-5.8; preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8.
[0036] In some embodiments, the composition of the present invention is a suspension. Wherein, the pH value of the suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the suspension is about 60-200nm, preferably 90-150nm, more preferably 90-135nm. The suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v). In some embodiments, the suspension contains docetaxel 2-10mg / ml, preferably 2-8mg / ml. The suspension is stable for at least 24 hours at 25°C, preferably at least 30 hours; it is stable for at least 7 days at 2-8°C, preferably at least 10 days.
[0037] In other embodiments, the composition of the present invention is a lyophilized powder. The particle size of the docetaxel albumin nanoparticles is about 60-200 nm, preferably 90-150 nm, and more preferably 90-135 nm. In some embodiments, the lyophilized powder contains sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9):1, preferably (1-7):1, preferably (1.5-4.5):1, and most preferably 2.25:1.
[0038] The lyophilized powder is freeze-dried from a suspension containing docetaxel albumin nanoparticles. The pH value of the suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, and more preferably 3.9-4.8. The particle size of the docetaxel albumin nanoparticles in the suspension is about 60-200nm, preferably 90-150nm, and more preferably 90-135nm. The suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), and more preferably 0.9%-1.8% (w / v). The suspension is stable at 25°C for at least 24 hours, preferably at least 30 hours; and stable at 2-8°C for at least 7 days, preferably at least 10 days.
[0039] The lyophilized powder is reconstituted with a reconstitution medium. The reconstitution medium is selected from water for injection, sodium chloride solution or glucose solution, preferably water for injection. The pH value of the reconstituted suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the reconstituted suspension is about 60-200nm, preferably 90-150nm, more preferably 90-135nm. The reconstituted suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v). The reconstituted isotonic suspension is stable at 25°C for at least 24 hours, preferably at least 30 hours; stable at 2-8°C for at least 7 days, preferably at least 10 days.
[0040] In some embodiments, the composition containing docetaxel albumin nanoparticles of the present invention is stable for at least 36 months at 25°C after freeze-drying. The "stable" mentioned here includes but is not limited to no significant degradation of docetaxel, no significant aggregation of protein nanoparticles, no significant increase in particle size, no significant change in docetaxel content, moisture, acidity, osmotic pressure or molar concentration. The "stable" can be one or more of the above-mentioned situations. In some embodiments, the "stable" is manifested as no significant change in the content of 7-epi-docetaxel and / or albumin polymers.
[0041] On the other hand, the present invention also provides a drug, which is prepared from the above-mentioned composition containing docetaxel albumin nanoparticles. The drug is in a clinically acceptable dosage form, preferably an injection, and more preferably a liquid injection or a lyophilized powder injection.
[0042] When the injection is a liquid injection, the pH value of the liquid injection is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the liquid injection is about 60-200nm, preferably 90-150nm, more preferably 90-135nm; the liquid injection contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9% (w / v). In some embodiments, the liquid injection contains 2-10mg / ml of docetaxel, preferably 2-8mg / ml. The liquid injection is stable for at least 24 hours at 25°C, preferably at least 30 hours; it is stable for at least 7 days at 2-8°C, preferably at least 10 days. The "stable" described here means that there is no precipitation of nanoparticles or turbidity of the liquid injection.
[0043] When the injection is a lyophilized powder injection, the lyophilized powder injection contains sodium chloride, and the weight ratio of sodium chloride:docetaxel is (0.75-9):1, preferably (1-7):1; preferably (1.5-4.5):1, and most preferably 2.25:1. The particle size of docetaxel albumin nanoparticles is about 60-200nm, preferably 90-150nm, and more preferably 90-135nm. The pH of the suspension for preparing the lyophilized powder injection before lyophilization is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, and more preferably 3.9-4.8. The suspension is stable at 25°C for at least 24 hours and at 2-8°C for at least 10 days.
[0044] The freeze-dried powder injection uses a reconstitution medium to reconstitute the suspension. The reconstitution medium is selected from water for injection, sodium chloride solution or glucose solution, preferably water for injection. The pH value of the reconstituted suspension obtained is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the reconstituted suspension is about 60-200nm, preferably 90-150nm, more preferably 90-135nm. The reconstituted suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9%. In some embodiments, the reconstituted suspension contains docetaxel 2-10mg / ml, preferably 2-8mg / ml. The reconstituted suspension is stable for at least 24 hours at 25°C, preferably at least 30 hours; it is stable for at least 7 days at 2-8°C, preferably at least 10 days.
[0045] The present invention also provides a method for preparing the composition, comprising the following steps:
[0046] (1) dissolving docetaxel in an organic solvent to obtain an organic phase solution;
[0047] (2) taking a human albumin solution, adding acid to adjust the pH value, and obtaining an acid-denatured albumin aqueous solution; and taking another salt solution;
[0048] (3) mixing the organic phase solution, the aqueous phase solution and the salt solution to carry the drug to obtain a drug-loaded solution;
[0049] (4) dialyzing to obtain a dialyzed suspension;
[0050] Wherein, before adding acid to adjust the pH value, step (2) optionally comprises the step of diluting the human albumin solution with water for injection to obtain an albumin dilution solution.
[0051] Wherein, step (2) optionally comprises an incubation step after adding acid to adjust the pH value.
[0052] Wherein, step (3) optionally comprises a cooling step after mixing the drug-loaded materials.
[0053] Wherein, step (4) optionally comprises, before dialysis, concentrating the drug-loaded solution obtained in step (3) to obtain a concentrated solution.
[0054] Wherein, after dialysis, step (4) optionally comprises a concentration or dilution step to adjust the concentration of docetaxel in the suspension after dialysis.
[0055] Wherein, step (4) optionally includes step (5) of sterilization filtration.
[0056] Wherein, step (5) optionally comprises step (6) of freeze-drying.
[0057] Wherein, the docetaxel in step (1) is in any form, preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate. Based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), and more preferably 1:(4.0-6.0).
[0058] Wherein, the organic solvent in step (1) is selected from solvents miscible with water, such as ethanol, methanol, acetone, DMSO, etc., preferably ethanol. Based on anhydrous docetaxel, the organic phase solution contains 45-90 mg / ml of docetaxel, preferably 45-70 mg / ml.
[0059] Wherein, the content of sodium octanoate in the human albumin solution in step (2) is not higher than 0.12 mmol / g protein, preferably not higher than 0.08 mmol / g protein, preferably 0.045-0.08 mmol / g protein.
[0060] Wherein, in step (2), the albumin diluent contains 6-25 mg / ml of albumin, preferably 10-20 mg / ml, more preferably 12-18 mg / ml, and more preferably 15 mg / ml.
[0061] Wherein, in step (2), the acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine hydrochloride. The pH value is preferably 3.5-5.5, preferably 3.5-5.0, more preferably 3.8-4.7, and more preferably 4.0-4.5.
[0062] Wherein, in step (2), the incubation refers to heating to 35°C-42°C, preferably 38°C-42°C, after adding acid to adjust the pH value; incubating for more than 30 minutes, preferably 30 minutes-60 minutes.
[0063] The salt solution in step (2) is selected from an aqueous solution of sodium chloride, potassium chloride, sodium sulfate or magnesium sulfate, preferably an aqueous solution of sodium chloride; the concentration of the salt solution is not less than 2%, preferably 2% to 35%, more preferably 10% to 20%.
[0064] Wherein, in step (3), the drug loading condition is to heat the organic phase solution and the aqueous phase solution to 35°C-42°C, preferably 38°C-42°C, and mix the three to load the drug.
[0065] The cooling in step (3) refers to cooling to below room temperature, preferably 0-20°C, more preferably 7-15°C.
[0066] Wherein, the concentrated solution in step (4) contains about 4-10 mg / ml of docetaxel, preferably 6-10 mg / ml, more preferably 7-9 mg / ml, and more preferably 8 mg / ml.
[0067] Wherein, step (4) dialyzes to remove excess small molecule compounds, and there is no particular restriction on the type and dosage of the dialysate and the molecular weight cutoff of the dialysis membrane, and those skilled in the art can make a choice based on common technical knowledge or experience. For the convenience of further preparation and clinical use, the dialysate is preferably an aqueous solution of a clinically acceptable osmotic pressure regulator, such as an aqueous solution of sodium chloride, glucose, phosphate or citrate. In some embodiments, sodium chloride solution is used as the dialysate for dialysis in step (4). The molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate is not less than 3 times that of the drug-carrying solution or the concentrated solution, preferably 3-10 times, and more preferably 3-6 times. The concentration of the sodium chloride solution is not higher than 1.8% (w / v), preferably 0.45%-1.8% (w / v), and more preferably 0.9%-1.8% (w / v).
[0068] In some embodiments, the human albumin solution used in step (2) needs to be adjusted in advance for the content of sodium octanoate. A person skilled in the art can select an appropriate method to adjust the content of sodium octanoate in the human albumin solution based on common technical knowledge or experience, including but not limited to dialysis.
[0069] In some embodiments, the method for adjusting the content of sodium caprylate in the human albumin solution is:
[0070] A commercially available human albumin solution is taken and diluted with water for injection or physiological saline to obtain a diluted albumin solution; the diluted albumin solution is dialyzed with water for injection or physiological saline as a dialysate to partially remove sodium octanoate, thereby obtaining a human albumin solution with a low sodium octanoate content.
[0071] In some embodiments, the dilution multiple of the human albumin solution is not less than 4 times, preferably 4-7 times. For the dialysis, the molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate can be determined by a person skilled in the art according to the required sodium octanoate content through routine tests. Preferably, the volume of the dialysate is about 3 times or more of the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times.
[0072] The human albumin solution with low sodium octanoate content contains sodium octanoate less than 0.16 mmol / g protein, preferably less than 0.12 mmol / g protein, preferably less than 0.10 mmol / g protein, preferably less than 0.08 mmol / g protein. The human albumin solution with low sodium octanoate content can be directly used to prepare the docetaxel albumin nanoparticle composition of the present invention, or can be mixed with other human albumin solutions with sodium octanoate content in proportion to obtain the desired content, and then used to prepare the docetaxel albumin nanoparticle composition.
[0073] On the other hand, the present invention also provides a composition containing docetaxel albumin nanoparticles, which is prepared by the above method.
[0074] In the preparation method, the dialysis step will remove excess small molecule compounds in the drug-carrying solution or the concentrated solution. For example, in some embodiments, step (2) uses acidic amino acids or acidic polypeptides to adjust the pH to prepare acid-denatured albumin; the dialysis step substantially removes excess acidic amino acids or acidic polypeptides; the composition contains almost no free acidic amino acids or acidic polypeptides. The "almost no free acidic amino acids or acidic polypeptides" means that the content of free acidic amino acids or acidic polypeptides in the composition is less than 0.25% (w / w) of docetaxel. For example, in some embodiments, cysteine hydrochloride or glutathione is used to adjust the pH to prepare acid-denatured albumin, and the content of free cysteine or glutathione in the composition is less than 0.25% (w / w) of docetaxel.
[0075] Furthermore, the present invention also provides a drug, which is prepared from the composition containing docetaxel albumin nanoparticles prepared by the above method. The drug is a clinically acceptable dosage form, preferably an injection, and more preferably a liquid injection or a lyophilized powder injection.
[0076] On the other hand, the present invention also provides a method for adjusting the content of sodium caprylate in a human albumin solution, comprising the following steps:
[0077] A commercially available human albumin solution is taken and diluted with water for injection or physiological saline to obtain a diluted albumin solution; the diluted albumin solution is dialyzed with water for injection or physiological saline as a dialysate to partially remove sodium octanoate, thereby obtaining a human albumin solution with a low sodium octanoate content.
[0078] In some embodiments, the dilution multiple of the human albumin solution is not less than 4 times, preferably 4-7 times. For the dialysis, the molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate can be determined by a person skilled in the art according to the required sodium octanoate content through routine tests. Preferably, the volume of the dialysate is about 3 times or more of the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times.
[0079] The human albumin solution with low sodium octanoate content contains sodium octanoate less than 0.16 mmol / g protein, preferably less than 0.12 mmol / g protein, preferably less than 0.10 mmol / g protein, and preferably less than 0.08 mmol / g protein.
[0080] The human albumin solution with low sodium octanoate content can be directly used to prepare the docetaxel albumin nanoparticle composition of the present invention, or can be mixed with human albumin solutions with other sodium octanoate contents in proportion to obtain a desired content, and then used to prepare the docetaxel albumin nanoparticle composition.
[0081] The content of docetaxel described in the present invention is calculated based on anhydrous docetaxel.
[0082] The numerical values or numerical ranges described in the present invention may fluctuate within the scope understood by those skilled in the art without affecting the implementation of the present invention, and the floating range is, for example, ±20%, or ±17%, or ±15%, or ±12%, ±10%, or ±9%, or ±8%, or ±7%, or ±6%, or ±5%, or ±4%, or ±3%, or ±2%, or ±1%.
[0083] The phrase “made from…” described in the present invention is an open-ended expression, which does not exclude the presence of other optional ingredients. For example, “the composition is made from docetaxel and acid-denatured albumin” should be understood as “the composition is made from a raw material composition comprising docetaxel and acid-denatured albumin as raw materials” or “the composition is made from a raw material with docetaxel and acid-denatured albumin as main components”.
[0084] The present invention surprisingly found that the heat stabilizer sodium octanoate in albumin has a great influence on the physical stability of the product. The reason is that sodium octanoate can compete with drugs to bind to the hydrophobic sites of albumin, reduce the binding force between the drug and the protein, and cause the nano suspension to be unstable. When a commercially available human albumin solution is directly used as an excipient (containing 0.16 mmol / g protein of sodium octanoate), the nanoparticles will settle within 10 hours; however, when the sodium octanoate content in the albumin solution is reduced to less than 0.08 mmol / g protein by dialysis, the stability of the prepared nanoparticles is greatly improved, and it can remain stable for at least 24 hours at 25°C, and can be stably placed for at least 10 days at 2-8°C.
[0085] Secondly, pH value is also an important factor affecting the physical stability of docetaxel albumin nanoparticles. The pH value of the docetaxel albumin nanoparticle suspension prepared by the prior art is above the isoelectric point of albumin. In order to maintain the stability of the suspension, a large amount of organic acid or its salt needs to be added as a stabilizer, resulting in a high drug osmotic pressure, which will cause obvious pain during clinical use and cause osmotic damage to local cells and tissues of the injection. However, the present application prepares docetaxel albumin nanoparticles with acid-denatured albumin and controls the content of sodium octanoate in the albumin solution. There is no need to add other salt stabilizers, and a stable isotonic suspension is reconstructed, which has little irritation to blood vessels.
[0086] In addition, CN103054798A teaches that the stability of nanoparticles prepared by anhydrous docetaxel is significantly better than that of docetaxel trihydrate and hemihydrate. However, in the technical solution of the present invention, the crystal water of docetaxel, i.e., anhydrous, hemihydrate, and trihydrate, has no effect on the stability of the prepared docetaxel albumin nanoparticle composition. This greatly expands the range of choices for the use of docetaxel and has great industrial application value.
[0087] The present invention provides a physically and chemically stable docetaxel albumin composition. The composition provided by the present invention, the accelerated and long-term stability studies show that 7-epidocetaxel and protein polymers change little, and the completed accelerated stability test shows that the lyophilized powder can be stably stored at 30°C and 25°C for 18 months. According to existing data, it is predicted that it can be stably stored at 30°C for at least 20 months and at 25°C or below for at least 36 months. The completed static stability observation test shows that the composition provided by the present invention, whether it is a suspension before lyophilization or a reconstructed suspension after lyophilization, can be stable at room temperature for at least 24 hours and at least 10 days under refrigerated conditions, without turbidity of the suspension or precipitation of nanoparticles; the stability study for a longer time is in progress. Compared with the situation that the reconstructed suspension of the commercially available product is only stable for 8 hours, the product of the present invention greatly reduces the clinical use restrictions. In addition, compared with the commercially available docetaxel injection (Taxotere, TAXOTERE), the docetaxel albumin composition provided by the present invention has a higher maximum tolerated dose (MTD) and less toxicity. Therefore, it is expected that the docetaxel albumin composition provided by the present invention can increase the clinical dosage of docetaxel and improve the safety of clinical use. DETAILED DESCRIPTION
[0088] The following examples are specific descriptions of the present invention and are not intended to limit the scope of the present invention.
[0089] Unless otherwise specified, the term "stable" as used in the examples means that there is no precipitation of nanoparticles or turbidity of the suspension.
[0090] Unless otherwise specified, the "reconstituted suspension" described in the examples is an isotonic suspension.
[0091] Example 1 Preparation of a composition of docetaxel and albumin
[0092] The formulation of the docetaxel albumin nanoparticle composition is as follows:
[0093] Table 1 Prescription of docetaxel albumin nanoparticle composition
[0094] Prescription Number 1-1 1-2 1-3 1-4 Anhydrous docetaxel 8g 8g 8g 8g Human serum albumin 36g 36g 36g 80g <![CDATA[Sodium chloride a > 18g 36g 9g 18g
[0095] Note: a is the sodium chloride content in the suspension before freeze-drying after conversion. The corresponding sodium chloride concentrations (w / v) in the dialysate are: prescription 1-10.9%; prescription 1-21.8%; prescription 1-30.45%; prescription 1-40.9%.
[0096] (1) Weigh 8 g of anhydrous docetaxel and dissolve it in 120 ml of ethanol to obtain an organic phase solution;
[0097] (2) Take a prescribed amount of human albumin solution (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 15 mg / ml albumin, then add an appropriate amount of cysteine hydrochloride to adjust the pH to 4.1, incubate at 42°C for 30 minutes, and obtain an acid-denatured albumin aqueous phase solution; prepare a 20% saline solution of sodium chloride with water for injection.
[0098] (3) The organic phase solution and the aqueous phase solution were heated to 42°C, the organic phase, aqueous phase and salt solution were mixed to carry the drug, and the resulting material was placed in an ice water bath and cooled to 15°C to obtain a drug-loaded solution;
[0099] (4) concentrating the drug-loaded solution to a docetaxel concentration of about 8 mg / ml to obtain a concentrated solution; dialyzing the concentrated solution 5 times using a sodium chloride solution as a dialysate, with a dialysis membrane molecular weight cutoff of 30 KDa, to obtain a dialyzed suspension; then, adding an appropriate amount of dialysate to adjust the concentration of the suspension to 4 mg / ml of docetaxel;
[0100] (5) sterilizing and filtering through a 0.45 μm + 0.2 μm membrane to obtain a suspension before lyophilization;
[0101] (6) taking the pre-lyophilized suspension obtained in step (5), lyophilizing to obtain a lyophilized powder.
[0102] The results showed that the dialysis step would reduce the content of sodium octanoate. At the end of the dialysis step, the concentration of sodium chloride in the post-dialysis suspension was basically the same as the initial concentration of sodium chloride in the dialysate. The particle size of the nanoparticles in the suspension was detected by dynamic light scattering, and the suspension was left to stand to observe the sedimentation phenomenon. The results in Table 2 showed that the content of sodium chloride in the dialysate had no significant effect on the particle size of docetaxel albumin nanoparticles in the pre-lyophilized suspension and the reconstituted suspension. The pre-lyophilized suspension and the reconstituted suspension of each prescription were left to stand at 25°C for 24 hours, and no turbidity or precipitation of the solution was observed; no turbidity or precipitation of the solution was observed when the suspension was left to stand at 2-8°C for 10 days. It is suggested that the pre-lyophilized suspension and the reconstituted suspension of each prescription are stable for at least 24 hours at 25°C and at least 10 days at 2-8°C. There is no significant change in stability before and after lyophilization.
[0103] Comparing the results of prescriptions 1-1 and 1-4, it can be seen that adjusting the dosage ratio of docetaxel and albumin has no significant effect on the particle size of the nanoparticles and the stability of the suspension.
[0104] In addition, the inventors also used high performance liquid chromatography to detect the content of cysteine in the suspension after dialysis with reference to the general rule 0512 of the fourth part of the 2020 edition of the Chinese Pharmacopoeia. The results showed that the suspension after dialysis contained almost no free cysteine (the content was less than 0.25% (w / w) of docetaxel).
[0105] The inventors also tested the pH value of the suspension before and after dialysis and found that the pH value of the suspension before and after dialysis remained substantially unchanged.
[0106] Table 2 Particle size and stability of docetaxel albumin nanoparticles with different formulations
[0107]
[0108]
[0109] Note: a. The freeze-dried powder is reconstituted into a suspension (isotonic suspension) using water for injection. Prescription 1-1 is reconstituted into an isotonic suspension containing 4 mg / ml of docetaxel; Prescription 1-2 is reconstituted into an isotonic suspension containing 2 mg / ml of docetaxel; Prescription 1-3 is reconstituted into an isotonic suspension containing 8 mg / ml of docetaxel; Prescription 1-4 is reconstituted into an isotonic suspension containing 4 mg / ml of docetaxel.
[0110] Example 2
[0111] Weigh docetaxel trihydrate (8 g based on anhydrous docetaxel) and dissolve it in 160 ml of anhydrous ethanol to obtain an organic phase solution; take a human albumin solution containing 16 g of albumin (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 10 mg / ml albumin, then add an appropriate amount of cysteine hydrochloride to adjust the pH to 4.5, incubate at 40°C for 1 hour, and obtain an acid-denatured albumin aqueous phase solution; prepare a 10% salt solution of sodium chloride with water for injection; The organic phase, aqueous phase and saline solution are heated to 40° C., the organic phase, aqueous phase and saline solution are mixed to carry the drug, and the resulting material is placed in an ice water bath and cooled to 18° C. to obtain a drug-loaded solution; the drug-loaded solution is concentrated to a docetaxel concentration of about 10 mg / ml to obtain a concentrated solution; the concentrated solution is dialyzed 6 times using an isotonic sodium chloride solution (0.9%, w / v) as a dialysate, and the molecular weight cutoff of the dialysis membrane is 30 KDa to obtain a post-dialysis suspension; sterilization filtration is performed through a 0.45 μm+0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilization is performed to obtain a lyophilized powder.
[0112] In the suspension before lyophilization, the particle size of docetaxel albumin nanoparticles was 101.3nm. After standing at 25℃ for 24 hours and at 2-8℃ for 10 days, no turbidity or precipitation of the solution was observed. The lyophilized powder was reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension). The particle size of docetaxel albumin nanoparticles did not change significantly and was 103.5nm. The reconstituted suspension was stood at 25℃ for 24 hours and at 2-8℃ for 10 days, and no turbidity or precipitation of the solution was observed. It is suggested that the suspension before lyophilization and the reconstituted suspension are stable for at least 24 hours at 25℃ and at least 10 days at 2-8℃.
[0113] High performance liquid chromatography showed that the suspension after dialysis contained almost no free cysteine (the content was about 0.13% (w / w) of docetaxel). The pH value of the suspension before and after dialysis remained basically unchanged.
[0114] Example 3
[0115] Weigh docetaxel hemihydrate (8 g based on anhydrous docetaxel) and dissolve it in 80 ml of 96% ethanol to obtain an organic phase solution; take a human albumin solution containing 50 g of albumin (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 20 mg / ml albumin, then add an appropriate amount of cysteine hydrochloride to adjust the pH to 3.9 to obtain an acid-denatured albumin aqueous phase solution; prepare a 2% saline solution of sodium chloride with water for injection; heat the organic phase solution and the aqueous phase solution to 35°C, and The solution and the salt solution are mixed to load the drug, and the obtained material is placed in an ice water bath to cool to 12° C. to obtain a drug-loaded solution; the drug-loaded solution is concentrated to a docetaxel concentration of about 7 mg / ml to obtain a concentrated solution, and the concentrated solution is dialyzed 5 times using an isotonic sodium chloride solution (0.9%, w / v) as a dialysate, and the molecular weight cutoff of the dialysis membrane is 10 KDa to obtain a post-dialysis suspension; sterilization filtration is performed through a 0.45 μm+0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilization is performed to obtain a lyophilized powder.
[0116] There was no significant difference in the particle size of docetaxel albumin nanoparticles between the suspension before lyophilization and the reconstituted suspension (isotonic suspension) obtained after reconstitution of the lyophilized powder with water for injection. The particle size was 119.7 nm before lyophilization and 121.3 nm after reconstitution. After standing at 25°C for 24 hours or at 2-8°C for 10 days, no turbidity or precipitation was observed in the suspension before lyophilization and the reconstituted suspension. It is suggested that the suspension before lyophilization and the reconstituted suspension are stable for at least 24 hours at 25°C and for at least 10 days at 2-8°C. HPLC detection showed that the suspension after dialysis contained almost no free cysteine (the content was about 0.21% (w / w) of docetaxel). The pH value of the suspension before and after dialysis remained basically unchanged.
[0117] Example 4 Effect of docetaxel usage form on the stability of the composition
[0118] Anhydrous docetaxel, docetaxel hemihydrate and docetaxel trihydrate (8 g each based on anhydrous docetaxel) were weighed and dissolved in 120 ml of ethanol to obtain an organic phase solution. A human albumin solution containing 36 g of albumin (the content of sodium octanoate was 0.08 mmol / g protein) was diluted with water for injection to a solution containing 20 mg / ml of albumin. An appropriate amount of cysteine hydrochloride was added to adjust the pH to 4.3, and the mixture was incubated at 42°C for 60 min to obtain an acid-denatured albumin aqueous phase solution. Sodium chloride was prepared with water for injection to a concentration of 10% salt solution; heating the organic phase solution and the aqueous phase solution to 42° C., mixing the organic phase solution, the aqueous phase solution and the salt solution to carry out drug loading, placing the obtained material in an ice water bath and cooling it to 12° C. to obtain a drug-loaded solution; concentrating the drug-loaded solution to contain docetaxel at a concentration of about 7 mg / ml to obtain a concentrated solution; using an isotonic sodium chloride solution as a dialysate to dialyze the concentrated solution 5 times, the molecular weight cutoff of the dialysis membrane is 30 KDa, to obtain a post-dialysis suspension; sterilizing and filtering through a 0.45 μm+0.2 μm membrane to obtain a pre-lyophilized suspension; lyophilizing to obtain a lyophilized powder.
[0119] As can be seen from the results in Table 3 below, docetaxel albumin nanoparticles were prepared using the same method using anhydrous docetaxel, docetaxel hemihydrate, and docetaxel trihydrate as raw materials, respectively. There was no significant difference in the particle size of the obtained nanoparticles, all of which were about 110 nm, and there was no significant change before and after lyophilization. In addition, there was no significant difference in the stability of the suspension before lyophilization and the reconstructed suspension (containing docetaxel 4 mg / ml) after the lyophilized powder was reconstituted with water for injection. No turbidity or precipitation of the solution was observed after standing for 24 hours at 25°C and standing for 10 days at 2-8°C. It is suggested that the above-mentioned suspension before lyophilization and the reconstructed suspension can be stable for at least 24 hours at 25°C and at least 10 days at 2-8°C. It can be seen that whether docetaxel contains water of crystallization does not affect the implementation of the present invention.
[0120] HPLC detection showed that the suspension after dialyzation contained almost no free cysteine (the content was less than 0.25% (w / w) of docetaxel).
[0121] Table 3 Effect of docetaxel usage form on the stability of the composition
[0122]
[0123] Example 5 Chemical Stability Study
[0124] The lyophilized powder containing docetaxel albumin nanoparticles obtained in prescription 1-1 in Example 1 was placed in a vial, a rubber stopper and an aluminum cap were pressed on, and stored under different storage conditions for 18 months. The relationship between the percentage content of 7-epi-docetaxel and the protein polymer content in the product and time was investigated. The results are shown in Table 4.
[0125] Table 4 Stability of the product of Example 1 Prescription 1-1
[0126]
[0127] Note: The acceptable limit used to define the stability of the pharmaceutical composition is "percentage content of 7-epidocetaxel ≤ 1.0%".
[0128] N / A* means the experiment has not yet reached that time point, so no data is available.
[0129] The results in Table 4 show that the generation of 7-epidocetaxel is related to the storage temperature. The higher the storage temperature, the faster the content of 7-epidocetaxel increases. The product of the present invention can effectively control the generation of 7-epidocetaxel. The results in Table 4 show that under the above three experimental conditions, the content of 7-epidocetaxel in the product of the present invention is within a controllable range (content ≤1.0%), and the protein polymer content does not change significantly. According to existing data predictions, the product of the present invention can be stably stored at 30°C for at least 20 months and stably stored at below 25°C for at least 36 months.
[0130] When the API raw material is other forms of docetaxel, such as hemihydrate and trihydrate, under the above test conditions, the changes in its chemical stability (percentage content of 7-epi-docetaxel and protein polymer content) are similar to those when anhydrous docetaxel is used as the raw material.
[0131] Chinese patent CN106137969A adds arginine, proline, etc. as inhibitors in the prescription, and believes that the use of arginine as an inhibitor has the best effect, and can be stored at 2-8°C for at least 24 months, or even up to 30 months. The data provided by the patent show that when the product is stored at 2-8°C for 12 months, the content of 7-epidocetaxel is between 0.5-0.61%; while the content of 7-epidocetaxel in the present invention is only about 0.41% when stored at 25°C for 12 months, and only 0.14% when stored at 2-8°C for 12 months, which is enough to show that the present invention can more effectively ensure the chemical stability of docetaxel compared with CN106137969A.
[0132] Example 6 Effect of Sodium Caprylate Content on Composition Stability
[0133] Weigh 8 g of anhydrous docetaxel and dissolve it in 120 ml of ethanol to obtain an organic phase solution;
[0134] Take human albumin solutions containing different concentrations of sodium octanoate (containing 36 grams of human albumin), dilute them with water for injection to 15 mg / ml of albumin, then add appropriate amount of cysteine hydrochloride to adjust the pH to 4.2, incubate at 42°C for 30 minutes to obtain an acid-denatured albumin aqueous phase solution; prepare a 15% saline solution of sodium chloride with water for injection;
[0135] The organic phase solution and the aqueous phase solution are heated to 42°C, the organic phase solution, the aqueous phase solution and the salt solution are mixed to carry the drug, and the resulting material is placed in an ice water bath and cooled to 15°C to obtain a drug-loaded solution; the drug-loaded solution is concentrated to a docetaxel concentration of about 8 mg / ml to obtain a concentrated solution; the concentrated solution is dialyzed 5 times using an isotonic sodium chloride solution as a dialysate (dialysis membrane molecular weight cutoff 30 KDa) to obtain a post-dialysis suspension; sterile filtration is performed through a 0.45 μm+0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilization is performed to obtain a lyophilized powder.
[0136] As shown in Table 5, the content of sodium octanoate in the raw material has no significant effect on the particle size of docetaxel albumin nanoparticles. However, when commercially available human albumin solution (containing 0.16 mmol / g protein of sodium octanoate) was used as the raw material to prepare docetaxel albumin nanoparticles, turbidity appeared after being placed at 25°C for 10 hours, and the physical stability of the suspension before lyophilization and the reconstructed isotonic suspension was poor. Reducing the content of sodium octanoate in the human albumin solution helps to improve the physical stability of the nanoparticle suspension. When the content of sodium octanoate in the human albumin solution is lower than 0.08 mmol / g protein, it can maintain a stable suspension state at 25°C for more than 24 hours, and the stable time is more than twice that of the sample containing 0.16 mmol / g protein of sodium octanoate. When the content of sodium octanoate in the human albumin solution is lower than 0.08 mmol / g protein, the suspension before lyophilization and the reconstructed isotonic suspension can be stably placed at 2-8°C for at least 10 days.
[0137] Table 5 Effect of the content of sodium octanoate on the stability of the composition
[0138]
[0139]
[0140] Note: a The lyophilized powder is reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension).
[0141] Example 7 Effect of pH value of aqueous solution on stability
[0142] The effect of the pH value of the aqueous solution on the stability of the product was compared. The process recipe and preparation method were based on the recipe 1-1 of Example 1, except that cysteine hydrochloride was used in step (2) to adjust the pH of the aqueous solution to 7.0, 6.5, 6.0, 5.5, 5.0, 4.7, 4.1, 3.8, and 3.5, respectively. The changes in the nanoparticle size and the stability of the suspension were observed in the suspension before freeze-drying and the reconstituted suspension.
[0143] The study found that when the pH of the aqueous solution was in the range of 3.5-5.5, the particle size of the obtained nanoparticles increased slightly with the increase of pH, but freeze-drying and reconstitution had no obvious effect on the particle size. When the pH of the aqueous solution was in the range of 3.5-5.5, the obtained pre-freeze-dried suspension and reconstituted suspension could maintain a stable suspension state at 25°C for more than 20 hours, and a stable suspension state at 2-8°C for at least 7 days. Furthermore, when the pH of the aqueous solution was in the range of 3.8-4.7, the pre-freeze-dried suspension and reconstituted suspension could still maintain a stable suspension state when left at 25°C for 30 hours and at 2-8°C for 10 days. Freeze-drying and reconstitution had no obvious effect on stability.
[0144] However, when the pH of the aqueous solution is above 6.0, the particle size of the obtained nanoparticles increases significantly, and the particle size of the nanoparticles increases to 180nm at pH 6.0. In addition, when the pH of the aqueous solution is higher than 6.0, the stability of the suspension decreases significantly, and turbidity appears within 1 hour, and the nanoparticles cannot be kept in a stable suspended state.
[0145] Table 6 Effect of aqueous protein pH on docetaxel albumin nanoparticles
[0146]
[0147]
[0148] Note: a The lyophilized powder is reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension).
[0149] Example 8 Preparation of human albumin solution with low sodium octanoate content
[0150] Example 8-1
[0151] A commercially available human albumin solution (the content of sodium octanoate is 0.16 mmol / g protein) is diluted with water for injection to a solution containing 15 mg / ml albumin to obtain an albumin dilution solution; the albumin dilution solution is dialyzed with water for injection as a dialysate (the molecular weight cut-off of the membrane package is 30 KDa) at a dialysis multiple of 6 times to partially remove the sodium octanoate in the protein to obtain a human albumin solution with a low sodium octanoate content.
[0152] The content of sodium octanoate in the obtained protein solution was detected by referring to the determination method of sodium octanoate in human albumin solution included in the Chinese Pharmacopoeia (Chinese Pharmacopoeia Part IV 3111, 2020 Edition). The results showed that the treated protein solution contained approximately 0.045 mmol / g protein of sodium octanoate.
[0153] Example 8-2
[0154] Take a commercially available human albumin solution (the content of sodium octanoate is 0.16mmol / g protein), dilute it with normal saline to a solution containing 12mg / ml albumin, and obtain an albumin dilution solution; use normal saline as a dialysate to dialyze the albumin dilution solution (the molecular weight cutoff of the membrane package is 10KDa), the dialysis multiple is 5 times, and the sodium octanoate in the protein is partially removed to obtain a human albumin solution with a low sodium octanoate content. After testing, the obtained human albumin solution with a low sodium octanoate content contains about 0.060mmol / g protein of sodium octanoate.
[0155] Example 8-3
[0156] Take a commercially available human albumin solution (the content of sodium octanoate is 0.16mmol / g protein), dilute it with water for injection to a solution containing 20mg / ml albumin, and obtain an albumin dilution solution; use water for injection as a dialysate to dialyze the albumin dilution solution (the molecular weight cut-off of the membrane package is 30KDa), the dialysis multiple is 3 times, and the sodium octanoate in the protein is partially removed to obtain a human albumin solution with a low sodium octanoate content. After testing, the obtained human albumin solution with a low sodium octanoate content contains about 0.080mmol / g protein of sodium octanoate.
[0157] For convenient storage or use, the human albumin solutions with low sodium octanoate content in the above Examples 8-1 to 8-3 can be further concentrated.
[0158] Example 9 Effect of Process on Protein Secondary Structure
[0159] According to the prescription and preparation method of Example 1-1, drug-loaded nanosuspensions and blank suspensions were prepared (without adding drug docetaxel in step (1)). Circular dichroism spectroscopy was used to investigate the proportion of each secondary structure of the protein in the human albumin solution, blank suspension and drug-loaded nanosuspension. The results are shown in Table 7.
[0160] The results showed that the blank suspension and drug-loaded nanosuspension prepared through the entire process had differences compared with the human albumin solution in terms of protein secondary structure α-helix, β-fold, turn and random coil, indicating that the process changed the secondary structure of albumin.
[0161] The research results suggest that even if the acid is removed in the dialysis step, the secondary structure of the acid-denatured albumin cannot be restored to the state before denaturation. Moreover, after binding with docetaxel, the secondary structure of the drug-loaded albumin further changes compared with the acid-denatured albumin without drug loading.
[0162] Table 7 Proportion of each secondary structure of the protein
[0163] Human albumin solution <![CDATA[Blank suspension a > <![CDATA[Drug-loaded nanosuspension a > α-helix (%) 39.5 23.9 27.9 β-fold (%) 15.1 11.7 4.4 Rotation angle (%) 16.8 26.2 30.1 Random curl (%) 28.6 38.2 37.6
[0164] Note: a: The blank suspension and drug-loaded nanosuspension described in Example 9 are both isotonic suspensions reconstituted after freeze-drying.
[0165] Example 10 was prepared according to Example 1 of CN 106137969 B (201510157393.1)
[0166] Weigh 1.5g of anhydrous docetaxel and dissolve it in 100ml of anhydrous ethanol. After ultrasonic dissolution, obtain an oil phase solution; take a human albumin solution containing 7.5g of albumin (concentration is 200mg / ml), dilute it with water for injection to a solution containing 6mg / ml albumin, and the total volume of the aqueous phase is 1250ml. Add 500mg of L-glutathione to the aqueous phase and incubate at 70℃ for 6min. Disperse the oil phase evenly into the aqueous phase under high shear of 1000rpm to obtain a suspension.
[0167] The suspension is white without opalescence, turbid visually, with a lot of precipitates visible, and precipitation occurs after 10 minutes of standing. The technicians believe that the obtained suspension has poor stability and cannot continue the subsequent operation according to the patent content. Therefore, the storage stability data of the product prepared by this research method is compared with the storage stability data provided in the patent. The inventor believes that it is sufficient to prove that the stability of the product in this research is significantly better than that of patent CN 106137969 B.
[0168]
[0169] N / A: This time point is not available in the stability study.
[0170] Example 11 Investigating the Effect of a Protein-Drug Ratio of 1.5 (while reducing the protein concentration to 5 mg / ml)
[0171] Weigh 1.6 g of anhydrous docetaxel and dissolve it in 23.7 ml of anhydrous ethanol to obtain an organic phase solution with a concentration of 67.5 mg / ml; take a human albumin solution containing 2.4 g of albumin (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 5 mg / ml of albumin, then add an appropriate amount of cysteine hydrochloride to adjust the pH to 4.0, incubate at 40°C for 0.5 h, and obtain an acid-denatured albumin aqueous phase solution; prepare a 14.4% saline solution of sodium chloride with water for injection; The organic phase solution and the aqueous phase solution are heated to 40° C., the organic phase, the aqueous phase and the salt solution are mixed to carry the drug, and the obtained material is placed in an ice water bath to cool to 18° C. to obtain a drug-loaded solution; the drug-loaded solution is concentrated to a docetaxel concentration of about 6 mg / ml to obtain a concentrated solution; the concentrated solution is dialyzed 5 times using an isotonic sodium chloride solution (0.9%, w / v) as a dialysate, and the molecular weight cutoff of the dialysis membrane is 30 KDa to obtain a post-dialysis suspension; sterilization filtration is performed through a 0.45 μm+0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilization is performed to obtain a lyophilized powder.
[0172] In the suspension before lyophilization, the particle size of docetaxel albumin nanoparticles was 91.38 nm, and it was completely turbid when left to stand for 20 hours at 25° C. The lyophilized powder was reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension), which was visually turbid.
[0173] Example 12 Investigating the effects of different dialysates
[0174] 1.8 g of anhydrous docetaxel was weighed and dissolved in 26.7 ml of anhydrous ethanol to obtain an organic phase solution with a concentration of 67.5 mg / ml; a human albumin solution containing 8.1 g of albumin (the content of sodium octanoate was 0.08 mmol / g protein) was taken and diluted with water for injection to a solution containing 15 mg / ml of albumin, and then an appropriate amount of cysteine hydrochloride was added to adjust the pH to 4.0, and incubated at 40° C. for 0.5 h to obtain an acid-denatured albumin aqueous phase solution; sodium chloride was prepared with water for injection to a saline solution with a concentration of 14.4%; the organic phase solution and the aqueous phase solution were heated to 40° C., the organic phase, the aqueous phase and the saline solution were mixed to carry the drug, and the obtained material was placed in an ice water bath and cooled to 18° C. to obtain a drug-loaded solution; the drug-loaded solution was concentrated to a docetaxel concentration of about 6 mg / ml to obtain a concentrated solution;
[0175] (1) using an isotonic glucose solution (5%, w / v) as a dialysate to dialyze the concentrate 5 times, with a dialysis membrane having a molecular weight cutoff of 30 KDa, to obtain a post-dialysis suspension; sterilizing and filtering through a 0.45 μm + 0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilizing to obtain a lyophilized powder.
[0176] In the suspension before lyophilization, the particle size of docetaxel albumin nanoparticles was 102.2nm. When standing at 25℃ for 16 hours, there was a lot of precipitation at the bottom. When standing at 2-8℃ for 16 hours, the transmittance decreased. The lyophilized powder was reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension). The particle size of docetaxel albumin nanoparticles did not change significantly and was 103.3nm. The reconstituted suspension was turbid after 2.5h at 25℃.
[0177] (2) using isotonic PBS buffer (pH 7.31, osmotic pressure 320 mOsmol / Kg) as a dialysate to dialyze the concentrate 5 times, with a dialysis membrane molecular weight cutoff of 30 KDa, to obtain a post-dialysis suspension; sterilizing and filtering through a 0.45 μm + 0.2 μm membrane to obtain a pre-lyophilized suspension; and lyophilizing to obtain a lyophilized powder.
[0178] In the suspension before lyophilization, the particle size of docetaxel albumin nanoparticles was 92.43nm. After standing at 25℃ for 16 hours, there was a slight precipitation at the bottom. After standing at 2-8℃ for 24 hours, the transmittance decreased. The lyophilized powder was reconstituted with water for injection to obtain a reconstituted suspension (isotonic suspension). The particle size of docetaxel albumin nanoparticles did not change significantly and was 90.91nm. Precipitation was observed in the reconstituted suspension at 25℃ for 2.5h.
[0179] Example 13 Comparison of the maximum tolerated dose (MTD) and toxicity of docetaxel injection (albumin-bound) (DTX-HSA) and docetaxel injection (TAXOTERE) in nude mice
[0180] 1. Drugs and test materials
[0181] 1.1 Test sample
[0182] Docetaxel (albumin-bound) for injection (DTX-HSA) is prepared by the preparation method of Example 1 using the prescription 1-1 in Example 1 of the present application.
[0183] 1.2 Comparator drugs
[0184] Docetaxel injection (trade name: Taxotere)
[0185]
[0186] 2. Experimental Animals
[0187]
[0188]
[0189] 3. Experimental Design
[0190] 3.1 Experimental Principle
[0191] This study defines the maximum tolerated dose (MTD) of the drug for intravenous administration to mice as the absence of death and irreversible toxic reactions in the animals, or no weight loss exceeding 15% for three consecutive days during the observation period. This dose is considered the maximum tolerated dose of an acute single administration.
[0192] 3.2 Dosage setting
[0193] The isotonic concentration of DTX-HSA after reconstitution is 3.801 mg / mL. According to the guidelines for the permissible volume of administration and blood collection for different routes of administration or blood collection for animals jointly issued by the European Federation of Pharmaceutical Industries and Associations and the European Center for Validation of Alternative Methods in 2001, the maximum volume of slow intravenous injection for mice is 25 mL / kg. The maximum dose can be given 3 times within 24 hours, and 285.1 mg / kg.
[0194] The doses preselected for this trial are:
[0195] Docetaxel for injection (albumin-bound): 285.1, 228.1, 182.5, 146.0 mg / kg (gradient 1.25).
[0196] Docetaxel injection (TAXOTERE): 187.5, 150, 120, 96 mg / kg (gradient 1.25).
[0197] 4. Experimental Methods
[0198] 4.1 Animal grouping and labeling
[0199] Healthy mice with small weight differences were selected and divided into 8 groups according to balanced weight, with 5 mice in each group, namely DTX-HSA 285.1, 228.1, 182.5, 146.0 mg / kg groups and TAXOTERE 187.5, 150, 120, 96 mg / kg groups.
[0200] 4.2 Administration
[0201] Administration: intravenous injection
[0202] Dosage frequency: 3 times within 24 hours, with an interval of 4 hours.
[0203] Dosing volume: 25mL / kg.
[0204] Administration rate: Slow push.
[0205] Dosage: Calculate the dosage based on the most recent weighing.
[0206] 4.3 Indicator Observation
[0207] General status observation: All animals were observed every day during the test period. Observation indicators included but were not limited to skin, fur, eyes, ears, nose, mouth, chest, abdomen, urogenital area, limbs, breathing, movement, urination, defecation and behavioral changes. Animal adverse reactions are shown in the table below.
[0208] Body weight: All animals were weighed once before the experiment, and animals with appropriate weight were selected for the experiment. Animals were weighed once a day at a fixed time.
[0209] Death and dying: For dead animals, the time of death should be recorded. For dying animals, the observation frequency should be increased and the time of death should be determined during the experiment.
[0210] 4.4 Evaluation indicators
[0211] During the observation period, there was no death, irreversible toxicity symptoms, or weight loss in mice. The maximum dose exceeding 15% for 3 consecutive days was considered the maximum tolerated dose (MTD) of the experimental drug.
[0212] 5. Experimental Results
[0213] 5.1 Death
[0214] No animal death was observed in the DTX-HSA and TAXOTERE administration groups.
[0215] 5.2 Clinical Observation
[0216] The animals in the DTX-HSA 285.1 and 228.1 mg / kg groups showed slight hind limb tremor from D4 and D7, respectively. The hind limb tremor of the animals in the 228.1 mg / kg group recovered on D20, and the hind limb tremor of the animals in the 285.1 mg / kg group recovered on D22. No obvious abnormalities were observed in the animals in the DTX-HSA 182.5 and 146.0 mg / kg groups.
[0217] Animals in the TAXOTERE 187.5 and 150 mg / kg groups showed mild to moderate hind limb tremors starting from D4 and D6, respectively. The hind limb tremor symptoms of animals in the 150 mg / kg group recovered on D19, and the hind limb tremor symptoms of animals in the 187.5 mg / kg group recovered on D24. No obvious abnormalities were observed in the animals in the TAXOTERE 120 and 96 mg / kg groups.
[0218] 5.3 Weight
[0219] In the DTX-HSA 285.1 mg / kg group, 1 / 5 animals lost more than 15% body weight on D5-D8, and 1 / 5 animals lost more than 15% body weight on D10, D12, and D13. No animals in other DTX-HSA-administered groups lost more than 15% body weight.
[0220] One out of five animals in the TAXOTERE 187.5 mg / kg group lost more than 15% of their body weight from D4 to D14, while no animal in the other TAXOTERE-administered groups lost more than 15% of their body weight.
[0221] Toxicity in mice after administration (n=5)
[0222]
[0223]
[0224] MTD: During the observation period, there was no death, no irreversible toxicity symptoms, and no weight loss of mice exceeding 15% of the maximum dose for 3 consecutive days. Observation time: 24 days.
[0225] 6. Conclusion
[0226] Under the conditions of this experiment, the MTD of DTX-HSA in nude mice was 228.1 mg / kg; the MTD of TAXOTERE in nude mice was 150.0 mg / kg.
Claims
1. A composition containing docetaxel albumin nanoparticles, characterized in that: The composition comprises docetaxel and acid-denatured albumin; the docetaxel is preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate.
2. A composition containing docetaxel albumin nanoparticles, characterized in that: The composition is made of docetaxel and acid-denatured albumin; the docetaxel is preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate.
3. The composition according to claim 1 or 2, characterized in that The acid-denatured albumin is obtained by adding acid to human albumin and then denaturing it to an appropriate pH value; preferably: (1) The acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids; the acidic amino acids or acidic polypeptides include cysteine hydrochloride and glutathione; the organic acids include citric acid and tartaric acid; the inorganic acids include hydrochloric acid and sulfuric acid; the acid is preferably cysteine hydrochloride, glutathione, and hydrochloric acid, and more preferably cysteine hydrochloride; and / or (2) The appropriate pH value is preferably 3.5 to 5.5, preferably 3.5 to 5.0, more preferably 3.8 to 4.7, more preferably 4.0 to 4.5; and / or (3) The content of sodium octanoate in the human albumin is not higher than 0.08 mmol / g protein; preferably 0.03-0.08 mmol / g protein, more preferably 0.04-0.08 mmol / g protein, and more preferably 0.04-0.07 mmol / g protein; and / or (4) Based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), and more preferably 1:(4.0-6.0).
4. The composition according to claim 1 or 2, characterized in that The particle size of the docetaxel albumin nanoparticles is 60-200 nm, preferably 90-150 nm, and more preferably 90-135 nm.
5. The composition according to claim 1 or 2, characterized in that The composition optionally contains an osmotic pressure regulator; the osmotic pressure regulator is selected from sodium chloride, glucose, phosphate or citrate; preferably, the osmotic pressure regulator is sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9):1, preferably (1-7):1, preferably (1.5-4.5):1, and most preferably 2.25:
1.
6. The composition according to claim 1 or 2, characterized in that The composition optionally comprises a pH adjusting agent.
7. The composition according to claim 1 or 2, characterized in that The composition is a suspension; the suspension contains 2-10 mg / ml of docetaxel, preferably 2-8 mg / ml; the pH value of the suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8; the suspension contains 0-1.8% (w / v) of sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v).
8. A lyophilized powder prepared from the composition of claim 7.
9. The composition according to claim 1 or 2, characterized in that The composition is a lyophilized powder; the lyophilized powder contains sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9):1, preferably (1-7):1, preferably (1.5-4.5):1, and most preferably 2.25:1; the lyophilized powder is freeze-dried from a suspension containing docetaxel albumin nanoparticles; the pH of the suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, and more preferably 3.9-4.
8.
10. A reconstituted suspension obtained by reconstitution of the lyophilized powder according to claim 8 or the composition according to claim 9 using a reconstitution medium; the reconstitution medium is selected from water for injection, sodium chloride solution or glucose solution, preferably water for injection; the pH of the reconstituted suspension is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.
8.
11. A drug, which is made from the composition according to any one of claims 1-7 and 9, the lyophilized powder according to claim 8, or the reconstituted suspension according to claim 10; the drug is in a clinically acceptable dosage form, preferably an injection, more preferably a liquid injection or a lyophilized powder injection.
12. A method for preparing a composition containing docetaxel albumin nanoparticles, comprising the following steps: (1) dissolving docetaxel in an organic solvent to obtain an organic phase solution; (2) taking a human albumin solution, adding acid to adjust the pH value, and obtaining an acid-denatured albumin aqueous solution; and taking another salt solution; (3) mixing the organic phase solution, the aqueous phase solution and the salt solution to carry the drug to obtain a drug-loaded solution; (4) Dialysis; in, Step (2) optionally comprises the step of diluting the human albumin solution with water for injection to obtain an albumin dilution solution before adding acid to adjust the pH value; Step (2) optionally comprises an incubation step after adding acid to adjust the pH value; Step (3) optionally comprises a cooling step after mixing the drug-loaded mixture; Step (4) optionally comprises the step of concentrating the drug-loaded solution obtained in step (3) to obtain a concentrated solution before dialysis; Step (4) optionally comprises a concentration or dilution step after dialysis; Optionally, step (5) of sterilizing and filtering is included after step (4); Optionally, step (6) of freeze-drying is included after step (5).
13. The preparation method according to claim 12, characterized in that: The docetaxel in step (1) is in any form, preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate; based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), and more preferably 1:(4.0-6.0); Alternatively, the organic solvent in step (1) is selected from solvents miscible with water, preferably ethanol, methanol, acetone, DMSO, and more preferably ethanol; based on anhydrous docetaxel, the organic phase solution contains 45-90 mg / ml of docetaxel, preferably 45-70 mg / ml.
14. The preparation method according to claim 12, characterized in that: The content of sodium octanoate in the human albumin solution in step (2) is not higher than 0.12 mmol / g protein, preferably not higher than 0.08 mmol / g protein, preferably 0.045-0.08 mmol / g protein; Alternatively, in step (2), the acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids; the acidic amino acids or acidic polypeptides include cysteine hydrochloride and glutathione; the organic acids include citric acid and tartaric acid; the inorganic acids include hydrochloric acid and sulfuric acid; the acid is preferably cysteine hydrochloride, glutathione, and hydrochloric acid, and more preferably cysteine hydrochloride; the pH value is preferably 3.5-5.5, preferably 3.5-5.0, more preferably 3.8-4.7, and more preferably 4.0-4.5; Alternatively, in step (2), the incubation refers to heating to 35°C-42°C, preferably 38°C-42°C, after adding acid to adjust the pH value; incubating for more than 30 minutes, preferably 30 minutes-60 minutes; Alternatively, the salt of the salt solution in step (2) is selected from sodium chloride, potassium chloride, sodium sulfate or magnesium sulfate, preferably sodium chloride; the concentration of the salt solution is not less than 2%, preferably 2% to 35%, more preferably 10% to 20%; Alternatively, in step (2), the albumin diluent is a solution containing 6-25 mg / ml albumin, preferably a solution containing 10-20 mg / ml albumin, more preferably a solution containing 12-18 mg / ml albumin, and more preferably a solution containing 15 mg / ml albumin.
15. The preparation method according to claim 12, characterized in that: In step (3), the drug loading condition is to raise the temperature of the organic phase solution and the aqueous phase solution to 35°C-42°C, preferably 38°C-42°C, and mix the organic phase solution, the aqueous phase solution and the salt solution to load the drug; Alternatively, the cooling in step (3) refers to cooling to below room temperature, preferably 0-20°C, more preferably 7-15°C.
16. The preparation method according to claim 12, characterized in that: In step (4), a sodium chloride solution is used as a dialysate for dialysis; the concentration of the sodium chloride solution is not higher than 1.8% (w / v), preferably 0.45%-1.8% (w / v), and more preferably 0.9%-1.8% (w / v); Alternatively, the molecular weight cut-off of the dialysis membrane used for dialysis in step (4) is 10-50 KDa, preferably 10-30 KDa, more preferably 10 KDa or 30 KDa; Alternatively, the volume of the dialysate used for dialysis in step (4) is not less than 3 times, preferably 3-10 times, more preferably 3-6 times, of the drug-carrying solution or the concentrated solution; Alternatively, the concentrated solution in step (4) contains 4-10 mg / ml of docetaxel, preferably 6-10 mg / ml, more preferably 7-9 mg / ml, and more preferably 8 mg / ml.
17. The preparation method according to claim 12, characterized in that: The human albumin solution described in step (2) is prepared by the following method: taking a commercially available human albumin solution, diluting it with water for injection or physiological saline to obtain a diluted albumin solution; dialyzing the diluted albumin solution with water for injection or physiological saline as a dialysate to partially remove sodium octanoate, thereby obtaining a human albumin solution with a low sodium octanoate content; the human albumin solution with a low sodium octanoate content is directly used as the human albumin solution described in step (2), or is mixed with other human albumin solutions with sodium octanoate contents in proportion to obtain a desired content and then used as the human albumin solution described in step (2).
18. The preparation method according to claim 17, characterized in that: The dilution multiple of the human albumin solution is not less than 4 times, preferably 4-7 times; Alternatively, the molecular weight cutoff of the dialysis membrane used in the dialysis is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa; the volume of the dialysate is more than 3 times the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times; Alternatively, the human albumin solution with low sodium octanoate content contains sodium octanoate less than 0.16 mmol / g protein, preferably less than 0.12 mmol / g protein, preferably less than 0.10 mmol / g protein, preferably less than 0.08 mmol / g protein.
19. A composition containing docetaxel albumin nanoparticles, prepared by the method according to any one of claims 12 to 18.
20. A drug prepared from the composition containing docetaxel albumin nanoparticles according to claim 19; the drug is in a clinically acceptable dosage form, preferably an injection, and more preferably a liquid injection or a lyophilized powder injection.
21. A method for reducing the content of sodium octanoate in a human albumin solution, characterized in that: Taking a commercially available human albumin solution, diluting it with water for injection or physiological saline to obtain a diluted albumin solution; using the water for injection or physiological saline as a dialysate to dialyze the diluted albumin solution; Preferably, the dilution multiple of the human albumin solution is not less than 4 times, preferably 4-7 times; Preferably, the molecular weight cutoff of the dialysis membrane used in the dialysis is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa; the volume of the dialysate is more than 3 times the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times.
Citation Information
Patent Citations
Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN103054798A
Docetaxel albumin nanoparticle pharmaceutical composition and preparation method and application thereof
CN106137969A
Docetaxel albumin nanoparticle drug composition, its preparation method and application
CN106137969B
Compositions and methods of delivery of pharmacological agents
US20050004002A1
Albumin pharmaceutical composition and preparation method therefor
WO2018059304A1
